Fibrovein ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
279	Huge venous malformation with cervical, oral and pharyngeal diffuse lesion	2

279. Huge venous malformation with cervical, oral and pharyngeal diffuse lesion

---

Clinical trials : 15 /  Drugs : 24 - (DrugBank : 10) / Drug target genes : 3 - Drug target pathways : 105

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2011-001455-37-NO (EUCTR)	21/12/2011	01/06/2011	Prospective randomized interventional study in patients with venous malformations.	Prospective randomized interventional study. Compare the effect of bleomycin and Tetradecyl Sodium Sulphate (Fibrovein) in the treatment of venous malformations. Clinical neurological and neurophysiological study of a subpopulation of patients with venous malformations.	Venous malformation MedDRA version: 13.1;Level: LLT;Classification code 10047229;Term: Venous malformation NOS;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Trade Name: Bleomycin Baxter Product Name: Bleomycin Trade Name: Fibrovein 3% Product Name: Fibrovein 3%	Department of Radiology, Oslo University Hospital, Norway	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Norway
2	NCT01347294 (ClinicalTrials.gov)	August 2011	11/4/2011	Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations	Compare the Effect of Bleomycin and Tetradecyl Sodium Sulphate in the Treatment of Venous Malformations	Venous Malformation	Drug: Bleomycin;Drug: Fibrovein;Drug: Bleomycin + Fibrovein	Oslo University Hospital	NULL	Recruiting	12 Years	80 Years	All	126	Phase 4	Norway